Peter Marks (physician)

Peter Marks is an American hematologist oncologist serving as the Director of the Center for Biologics Evaluation and Research within the Food and Drug Administration. He was appointed to the position in 2016 after previously serving as deputy director.

Peter Marks
Director of the Center for Biologics Evaluation and Research
Assumed office
2016
PresidentBarack Obama
Donald Trump
Joe Biden
Preceded byKaren Midthun
Member of the White House Coronavirus Task Force
Assumed office
May 2020
PresidentDonald Trump
Personal details
EducationColumbia University (BS)
New York University (MD, PhD)
Scientific career
FieldsOncology
InstitutionsBrigham and Women's Hospital
Yale University

Education

Marks earned a Bachelor of Science degree from Columbia University, followed by a Doctor of Medicine and PhD in cell and molecular biology from New York University in the lab of Fredrick Maxfield. As an undergraduate, he volunteered at Mount Sinai St. Luke's in New York City, where he worked in the radioimmunoassay lab. He completed an internal medicine residency and Oncology training at the Brigham and Women's Hospital.[1][2]

Career

After completing his training, Marks worked at the Brigham and Women's Hospital as a clinician-scientist, and later served as Clinical Director of Hematology. He then worked in the pharmaceutical industry, where he worked on the development of hematology and oncology products. He later managed the Adult Leukemia Service at Yale University and served as the Chief Clinical Officer of the Yale New Haven Hospital Cancer Center. Marks joined the Center for Biologics Evaluation and Research as deputy director in 2012, and was promoted to director in 2016.[3][4]

In May 2020, he was selected to serve as a member of the White House Coronavirus Task Force,[5] although he left a few days later over concerns that his participation would represent a conflict with his position at FDA.[6] Marks also played a role in establishing Operation Warp Speed, a partnership between the federal government and various private companies to develop a COVID-19 vaccine, but left the project in May 2020 shortly after it was launched because Marks believed he would be more useful in his role as chief regulator of vaccines as the Director of FDA's Center for Biologics Evaluation and Research.[7][8][9]

References
  1. admin (2019-02-01). "Pulling Back the Curtain: Peter Marks, MD, PhD". ASH Clinical News. Retrieved 2020-08-31.
  2. "Peter Marks, MD, PhD - BIO Digital | BIO". www.bio.org. Retrieved 2020-08-31.
  3. Commissioner, Office of the (2020-02-03). "Peter Marks | FDA". U.S. Food and Drug Administration. Retrieved 2020-08-31.
  4. "BIO 2019 - Profile - Peter Marks". bio2019.zerista.com. Retrieved 2020-08-31.
  5. "New Members of the White House Coronavirus Task Force Announced". The White House. Retrieved 2020-08-31.
  6. https://www.nbcnews.com/news/amp/ncna1222361
  7. "FDA's vaccine head quits Operation Warp Speed days after joining". www.beckershospitalreview.com. Retrieved 2020-08-31.
  8. McGinley, Laurie. "Meet the most important federal official you probably don't know — the man who holds the fate of the coronavirus vaccine in his hands". Washington Post. ISSN 0190-8286. Retrieved 2020-08-31.
  9. Owermohle, Sarah. "FDA struggles to remain independent amid race for virus cure". POLITICO. Retrieved 2020-08-31.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.